

論文発表

原著

1. Canonica GW, Spanevello A, de Llano LP, Domingo Ribas C, Blakey JD, Garcia G, Inoue H, Dalcolmo M, Yang D, Mokashi S, Kurne A, Butta AK. Is asthma control more than just an absence of symptoms? An expert consensus statement. *Respir Med*. 2022 Oct; 202: 106942.
2. Nagata K, Horie T, Chohnabayashi N, Jinta T, Tsugitomi R, Shiraki A, Tokioka F, Kadowaki T, Watanabe A, Fukui M, Kitajima T, Sato S, Tsuda T, Kishimoto N, Kita H, Mori Y, Nakayama M, Takahashi K, Tsuboi T, Yoshida M, Hataji O, Fuke S, Kagajo M, Nishine H, Kobayashi H, Nakamura H, Okuda M, Tachibana S, Takata S, Osoreda H, Minami K, Nishimura T, Ishida T, Terada J, Takeuchi N, Kohashi Y, Inoue H, Nakagawa Y, Kikuchi T, Tomii K. Home High-Flow Nasal Cannula Oxygen Therapy for Stable Hypercapnic COPD: A Randomized Trial. *Am J Respir Crit Care Med*. 2022 Dec 1; 206(11): 1326-1335.
3. Tanigawa K, Misono S, Mizuno K, Asai S, Suetsugu T, Uchida A, Kawano M, Inoue H, Seki N. MicroRNA signature of small-cell lung cancer after treatment failure: impact on oncogenic targets by miR-30a-3p. *Mol Oncol*. 2023 Feb; 17(2): 328-343.
4. Takahashi K, Kawayama T, Takamori A, Tashiro H, Kinoshita T, Takagi K, Yamasaki K, Machida K, Kawaguchi A, Yatera K, Inoue H; TRACK (Triple therapy for Japanese with mild to moderate COPD in Kyushu) study investigator group.
Efficacy and safety of once-daily single-inhaler triple therapy for mild-to-moderate chronic obstructive pulmonary disease: a study protocol for a randomised and interventional study. *BMJ Open Respir Res*. 2023 May; 10(1): e001607.
5. Tomioka Y, Suetsugu T, Seki N, Tanigawa K, Hagihara Y, Shinmura M, Asai S, Kikkawa N, Inoue H, Mizuno K.
The Molecular Pathogenesis of Tumor-Suppressive miR-486-5p and miR-486-3p Target Genes: GINS4 Facilitates Aggressiveness in Lung Adenocarcinoma. *Cells*. 2023 Jul 18; 12(14): 1885.
6. Tanigawa K, Tomioka Y, Misono S, Asai S, Kikkawa N, Hagihara Y, Suetsugu T, Inoue H, Mizuno K, Seki N.
Minichromosome maintenance proteins in lung adenocarcinoma: Clinical significance and therapeutic targets. *FEBS Open Bio*. 2023 Sep; 13(9): 1737-1755.

7. Kawayama T, Takahashi K, Ikeda T, Fukui K, Makita N, Tashiro N, Saito J, Shirai T, Inoue H. Exacerbation rates in Japanese patients with obstructive lung disease: A subanalysis of the prospective, observational NOVELTY study. *Allergol Int*. 2023 Sep 1: S1323-8930(23)00079-5.
8. Canonica GW, Spanevello A, de Llano LP, Ribas CD, Blakey JD, Garcia G, Inoue H, Dalcolmo M, Yang D, Mokashi S, Kurne A, Butta AK. Asthma control conundrum in clinical practice - Data from a two-stage Delphi survey and literature review. *Data Brief*. 2023 Jul 18 ; 50: 109422.

総説

1. 井上博雅 : As-needed IOS-formoterol. *呼吸器内科*. 2022; 42(3): 335-338
2. 高木 弘一, 井上 博雅 : 【COPD(慢性閉塞性肺疾患)診断と治療のためのガイドライン 2022 を読み解く】 安定期 COPD に対して, LABA+ICS と LAMA+LABA のいずれかを推奨するか? *呼吸器内科 (1884-2887)* . 2022.10; 42 巻 4 号: 362-367.
3. Nomura N, Matsumoto H, Yokoyama A, Nishimura Y, Asano K, Niimi A, Tohda Y, Harada N, Nagase H, Nagata M, Inoue H, Kondo M, Horiguchi T, Miyahara N, Hizawa N, Hojo M, Hattori N, Hashimoto N, Yamasaki A, Kadowaki T, Kimura T, Miki M, Taniguchi H, Toyoshima M, Kawamura T, Matsuno O, Sato Y, Sunadome H, Nagasaki T, Oguma T, Hirai T; BEXAS study. Nationwide survey of refractory asthma with bronchiectasis by inflammatory subtypes. *Respir Res*. 2022 Dec 20; 23(1): 365.
4. 松山崇弘, 高木弘一, 井上博雅 : 喘息と COPD のオーバーラップ (ACO) *日本医事新報*. 2022.12; 5148: 40-41
5. Kurose K, Sakaeda K, Fukuda M, Sakai Y, Yamaguchi H, Takemoto S, Shimizu K, Masuda T, Nakatomi K, Kawase S, Tanaka R, Suetsugu T, Mizuno K, Hasegawa T, Atarashi Y, Irino Y, Sato T, Inoue H, Hattori N, Kanda E, Nakata M, Mukae H, Oga T, Oka M. Immune checkpoint therapy and response biomarkers in non-small-cell lung cancer: Serum NY-ESO-1 and XAGE1 antibody as predictive and monitoring markers. *Adv Clin Chem*. 2023; 112: 155-204.
6. Levy ML, Bacharier LB, Bateman E, Boulet LP, Brightling C, Buhl R, Brusselle G, Cruz AA, Drazen JM, Duijts L, Fleming L, Inoue H, Ko FWS, Krishnan JA, Mortimer K, Pitrez PM, Sheikh A, Yorgancioğlu A, Reddel HK. Key recommendations for primary care from the 2022 Global Initiative for Asthma (GINA) update. *NPJ Prim Care Respir Med*. 2023 Feb 8; 33(1): 7.

7. Matsuyama T, Machida K, Mizuno K, Matsuyama H, Dotake Y, Shinmura M, Takagi K, Inoue H. The Functional Role of Group 2 Innate Lymphoid Cells in Asthma. *Biomolecules*. 2023 May 26; 13(6): 893.
8. Levy ML, Bateman ED, Allan K, Bacharier LB, Bonini M, Boulet LP, Bourdin A, Brightling C, Brusselle G, Buhl R, Chakaya MJ, Cruz AA, Drazen J, Ducharme FM, Duijts L, Fleming L, Inoue H, Ko FWS, Krishnan JA, Masekela R, Mortimer K, Pitrez P, Salvi S, Sheikh A, Reddel HK, Yorgancıoğlu A. Global access and patient safety in the transition to environmentally friendly respiratory inhalers: the Global Initiative for Asthma perspective. *Lancet*. 2023 Sep 16; 402(10406): 1012-1016.

症例

1. 窪田 幸司, 水野 圭子, 安田 俊介, 松山 崇弘, 濱崎 哲郎, 井上 博雅：アテゾリズマブ投与後に抗リカバリン抗体陽性の網膜症を発症した小細胞肺癌の1例. *日本呼吸器学会誌*(2186-5876). 2022.11; 11 巻 6 号: 345-349
2. Matsuyama T, Tomioka Y, Matsuyama H, Kamenohara Y, Tanigawa K, Dotake Y, Hagihara Y, Takagi K, Machida K, Inoue H. Severe asthma remaining well-controlled after mepolizumab discontinuation: A case report and literature review. *Respirol Case Rep*. 2023 May 11; 11(6): e01158.

その他

1. 柴藤 俊彦, 安田 俊介, 清水 健：肝機能障害を契機に肝生検にて診断したサルコイドーシスの1例. *鹿児島市医報*. 2023.2.20; 62(3): 39-40.
2. 井上 博雅：COPD（慢性閉塞性肺疾患）ってどんな病気？. *オムロンヘルスケア HP 生活習慣病ガイド*. 2023